The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Open accessAbstract
Breast cancer is the most commonly diagnosed cancer in women. Metastasis is the primary cause of mortality for breast cancer patients. Multiple mechanisms underlie breast cancer metastatic dissemination, including the interleukin-6 (IL-6)-mediated signaling pathway. IL-6 is a pleiotropic cytokine that plays an important role in multiple physiological processes including cell proliferation, immune surveillance, acute inflammation, metabolism, and bone remodeling. IL-6 binds to the IL-6 receptor (IL-6Rα) which subsequently binds to the glycoprotein 130 (gp130) receptor creating a signal transducing hexameric receptor complex. Janus kinases (JAKs) are recruited and activated; activated JAKs, in turn, phosphorylate signal transducer and activator of transcription 3 (STAT3) for activation, leading to gene regulation. Constitutively active IL-6/JAK/STAT3 signaling drives cancer cell proliferation and invasiveness while suppressing apoptosis, and STAT3 enhances IL-6 signaling to promote a vicious inflammatory loop. Aberrant expression of IL-6 occurs in multiple cancer types and is associated with poor clinical prognosis and metastasis. In breast cancer, the IL-6 pathway is frequently activated, which can promote breast cancer metastasis while simultaneously suppressing the anti-tumor immune response. Given these important roles in human cancers, multiple components of the IL-6 pathway are promising targets for cancer therapeutics and are currently being evaluated preclinically and clinically for breast cancer. This review covers the current biological understanding of the IL-6 signaling pathway and its impact on breast cancer metastasis, as well as, therapeutic interventions that target components of the IL-6 pathway including: IL-6, IL-6Rα, gp130 receptor, JAKs, and STAT3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Khaki‐Khatibi, F., Ghorbani, M., Sabzichi, M., Ramezani, F., & Mohammadian, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.183 · Cited by 27
RetractedSiegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“Since the cloning of IL-6 cDNA by the Hirano and Kishimoto group in 1986 (27, 28), it became evident that IL-6 function was not limited to the immune system as the cDNA sequence maintained homology to other identified proteins: B cell stimulatory factor-2, Hepatocytestimulating factor, Hybridoma plasmacytoma growth fa…”
BackgroundA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Gauldie, J., Richards, C., Harnish, D., Lansdorp, P., & Baumann, H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7251 · Cited by 1,635
A new protein containing an SH2 domain that inhibits JAK kinases
Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Molecular cloning and expression of an IL-6 signal transducer, gp130
Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., & Kishimoto, T. (1990) · Cell · doi:10.1016/0092-8674(90)90411-7 · Cited by 1,039
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980
The molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., Zhang, C., Lifshitz, V., Song, J., Yuan, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.001 · Cited by 825
Interleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., & Hirano, T. (1996) · Immunity · doi:10.1016/s1074-7613(00)80501-4 · Cited by 652
Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex
Boulanger, M. J., Chow, D.-C., Brevnova, E. E., & Garcia, K. C. (2003) · Science · doi:10.1126/science.1083901 · Cited by 642
Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses
Jostock, T., Müllberg, J., Özbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M. F., & Rose‐John, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.01867.x · Cited by 641
Lo, H.-W., Hsu, S.-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N., & Hung, M.-C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0575 · Cited by 625
Self-citationSuppressors of cytokine signaling and immunity
Kubo, M., Hanada, T., & Yoshimura, A. (2003) · Nature Immunology · doi:10.1038/ni1012 · Cited by 618
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Mease, P., Hall, S., FitzGerald, O., van der Heijde, D., Merola, J. F., Avila-Zapata, F., Cieślak, D., Graham, D., Wang, C., Menon, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615975 · Cited by 571
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
STAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
Self-citationInterleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose-John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 509
Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins
Shuai, K., Ziemiecki, A., Wilks, A. F., Harpur, A. G., Sadowski, H. B., Gilman, M. Z., & Darnell, J. E. (1993) · Nature · doi:10.1038/366580a0 · Cited by 509
The soluble interleukin‐6 receptor is generated by shedding
Mülberg, J., Schooltink, H., Stoyan, T., Günther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. C., & Rose‐John, S. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230226 · Cited by 506
EMT, cancer stem cells and autophagy; The three main axes of metastasis
Babaei, G., Aziz, S. G.-G., & Jaghi, N. Z. Z. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110909 · Cited by 506
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia · doi:10.1593/neo.13706 · Cited by 494
Zilberstein, A., Ruggieri, R., Korn, J. H., & Revel, M. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04531.x · Cited by 487
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 450
Weng, Y.-S., Tseng, H.-Y., Chen, Y.-A., Shen, P.-C., Al Haq, A. T., Chen, L.-M., Tung, Y.-C., & Hsu, H.-L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0988-0 · Cited by 444
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10833 · Cited by 435
Soluble cytokine receptors are present in normal human urine.
Novick, D., Engelmann, H., Wallach, D., & Rubinstein, M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.4.1409 · Cited by 434
Guschin, D., Rogers, N., Briscoe, J., Witthuhn, B., Watling, D., Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P., & Stark, G. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07128.x · Cited by 433
Michalaki, V, Syrigos, K., Charles, P., & Waxman, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601814 · Cited by 406
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A. L., Möller-Hackbarth, K., Bartsch, H. S., et al. (2017) · Nature Immunology · doi:10.1038/ni.3632 · Cited by 386
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study
Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15856 · Cited by 355
Serum interleukin‐6 levels reflect the disease status of colorectal cancer
Chung, Y., & Chang, Y. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10269 · Cited by 353
Structural analysis of the sequence coding for an inducible 26‐kDa protein in human fibroblasts
HAEGEMAN, G., CONTENT, J., VOLCKAERT, G., DERYNCK, R., TAVERNIER, J., & FIERS, W. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb09931.x · Cited by 337
Barrionuevo, P., Kapoor, E., Asi, N., Alahdab, F., Mohammed, K., Benkhadra, K., Almasri, J., Farah, W., Sarigianni, M., Muthusamy, K., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00192 · Cited by 337
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 334
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
McLoughlin, R. M., Jenkins, B. J., Grail, D., Williams, A. S., Fielding, C. A., Parker, C. R., Ernst, M., Topley, N., & Jones, S. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501794102 · Cited by 333
Real, P. J., Sierra, A., de Juan, A., Segovia, J. C., Lopez-Vega, J. M., & Fernandez-Luna, J. L. (2002) · Oncogene · doi:10.1038/sj.onc.1206004 · Cited by 321
Wollenhaupt, J., Lee, E.-B., Curtis, J. R., Silverfield, J., Terry, K., Soma, K., Mojcik, C., DeMasi, R., Strengholt, S., Kwok, K., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1866-2 · Cited by 320
Sheppard, M., Laskou, F., Stapleton, P. P., Hadavi, S., & Dasgupta, B. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1316909 · Cited by 318
Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992) · Cytokine · doi:10.1016/1043-4666(92)90043-q · Cited by 316
Walter, M., Liang, S., Ghosh, S., Hornsby, P. J., & Li, R. (2009) · Oncogene · doi:10.1038/onc.2009.130 · Cited by 312
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3051 · Cited by 307
Ryan, Q., Ibrahim, A., Cohen, M. H., Johnson, J., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0816 · Cited by 307
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
Mechanisms of immune evasion in breast cancer
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 291
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2203 · Cited by 285
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
Burke, W. M., Jin, X., Lin, H.-J., Huang, M., Liu, R., Reynolds, R. K., & Lin, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204990 · Cited by 269
Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., & Bromberg, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404100101 · Cited by 254
Kozłowski, L., Zakrzewska, I., Tokajuk, P., & Wojtukiewicz, M. Z. (2003) · PubMed · Cited by 248
STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition
Fukada, T., Ohtani, T., Yoshida, Y., Shirogane, T., Nishida, K., Nakajima, K., Hibi, M., & Hirano, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6670 · Cited by 247
Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction
Kaptein, A., Paillard, V., & Saunders, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.5961 · Cited by 245
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis
Siersbæk, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., Johnston, S. J., Joosten, S. E. P., Green, A. R., Kumar, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.007 · Cited by 245
Berishaj, M., Gao, S. P., Ahmed, S., Leslie, K., Al-Ahmadie, H., Gerald, W. L., Bornmann, W., & Bromberg, J. F. (2007) · Breast Cancer Research · doi:10.1186/bcr1680 · Cited by 236
Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Ihnat, M. A., Shenoy, S. S., Kulp, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2468 · Cited by 234
Molecular cloning and expression of hybridoma growth factor in Escherichia coli.
Brakenhoff, J. P. J., de Groot, E. R., Evers, R. F., Pannekoek, H., & Aarden, L. A. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4116 · Cited by 229
Studebaker, A. W., Storci, G., Werbeck, J. L., Sansone, P., Sasser, A. K., Tavolari, S., Huang, T., Chan, M. W. Y., Marini, F. C., Rosol, T. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0400 · Cited by 229
Badache, A., & Hynes, N. E. (2001) · PubMed · Cited by 219
Impact of breast cancer subtypes and patterns of metastasis on outcome
Kast, K., Link, T., Friedrich, K., Petzold, A., Niedostatek, A., Schoffer, O., Werner, C., Klug, S. J., Werner, A., Gatzweiler, A., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3341-3 · Cited by 209
Alvarez, J. V., Febbo, P. G., Ramaswamy, S., Loda, M., Richardson, A., & Frank, D. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4281 · Cited by 202
Hennigs, A., Riedel, F., Gondos, A., Sinn, P., Schirmacher, P., Marmé, F., Jäger, D., Kauczor, H.-U., Stieber, A., Lindel, K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2766-3 · Cited by 199
Role of Stat3 in suppressing anti-tumor immunity
Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196
IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
Lo, C.-W., Chen, M.-W., Hsiao, M., Wang, S., Chen, C.-A., Hsiao, S.-M., Chang, J.-S., Lai, T.-C., Rose-John, S., Kuo, M.-L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1496 · Cited by 193
Lin, L., Hutzen, B., Li, P.-K., Ball, S., Zuo, M., DeAngelis, S., Foust, E., Sobo, M., Friedman, L., Bhasin, D., et al. (2010) · Neoplasia · doi:10.1593/neo.91196 · Cited by 192
Chang, C. H., Hsiao, C. F., Yeh, Y. M., Chang, G. C., Tsai, Y. H., Chen, Y. M., Huang, M. S., Chen, H. L., Li, Y. J., Yang, P. C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27892 · Cited by 189
Breast cancer bone metastases: pathogenesis and therapeutic targets
Brook, N., Brook, E., Dharmarajan, A., Dass, C. R., & Chan, A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.003 · Cited by 186
Evaluation of potential Stat3-regulated genes in human breast cancer
Hsieh, F.-C., Cheng, G., & Lin, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.075 · Cited by 180
A novel IL‐23p19/Ebi3 (IL‐39) cytokine mediates inflammation in Lupus‐like mice
Wang, X., Wei, Y., Xiao, H., Liu, X., Zhang, Y., Han, G., Chen, G., Hou, C., Ma, N., Shen, B., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546095 · Cited by 175
Yang, L., Wang, L., Lin, H.-K., Kan, P.-Y., Xie, S., Tsai, M.-Y., Wang, P.-H., Chen, Y.-T., & Chang, C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00792-7 · Cited by 168
Yuan, Y. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1275 · Cited by 166
Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel, F., Zaiss, I., Herzog, D., Götte, K., Naim, R., & Hörmann, K. (2005) · PubMed · Cited by 162
CHUNG, S. S., GIEHL, N., WU, Y., & VADGAMA, J. V. (2014) · International Journal of Oncology · doi:10.3892/ijo.2013.2195 · Cited by 161
Li, H., Xiao, H., Lin, L., Jou, D., Kumari, V., Lin, J., & Li, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401144z · Cited by 161
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
Vogel, V. G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.51 · Cited by 158
Interleukins 1 and 6 as main mediators of inflammation and cancer
Dmitrieva, O., Shilovskiy, I. P., Khaitov, M. R., & Grivennikov, S. I. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020024 · Cited by 155
Stover, D. G., del Alcazar, C. R. G., Brock, J. E., Guo, H., Overmoyer, B. A., Balko, J. M., Xu, Q., Bardia, A., Tolaney, S. M., Gelman, R. S., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0060-z · Cited by 154
Elevated Serum Interleukin-6 Levels in Patients with Pancreatic Cancer
Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., & Kakizoe, T. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.1.12 · Cited by 153
IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus
Chen, M., Chen, P.-T., Lu, M. S., Lin, P. Y., Chen, W., & Lee, K. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-26 · Cited by 151
Tamm, I., Cardinale, I. R., Krueger, J. G., Murphy, J. S., May, L. T., & Sehgal, P. B. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.5.1649 · Cited by 149
Barbieri, I., Pensa, S., Pannellini, T., Quaglino, E., Maritano, D., Demaria, M., Voster, A., Turkson, J., Cavallo, F., Watson, C. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2840 · Cited by 148 · cited 1×
“Because STAT3 is constitutively active in the majority of breast cancers and plays an important role in mediating breast cancer growth, migration, and metastasis, this review will focus on the IL-6/JAK/STAT3 signaling cascade (95, 103, 104).”
BackgroundLee, J., Hahm, E., & Singh, S. V. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq175 · Cited by 147
Gyamfi, J., Lee, Y.-H., Eom, M., & Choi, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27184-9 · Cited by 144
Jiang, M., Chen, J., Zhang, W., Zhang, R., Ye, Y., Liu, P., Yu, W., Wei, F., Ren, X., & Yu, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01840 · Cited by 139
Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine · doi:10.1006/cyto.2002.2012 · Cited by 134
Lewis-Wambi, J. S., Kim, H., Curpan, R. F., Grigg, R., Sarker, M. A., & Jordan, V. C. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072249 · Cited by 128
Jones, L., Broz, M. L., Ranger, J. J., Ozcelik, J., Ahn, R., Zuo, D., Ursini‐Siegel, J., Hallett, M. T., Krummel, M. F., & Muller, W. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2770 · Cited by 128
Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer
Feng, L., Qi, Q., Wang, P., Chen, H., Chen, Z., Meng, Z., & Liu, L. (2018) · Journal of International Medical Research · doi:10.1177/0300060518800588 · Cited by 124
Barrueco, R. R., Yu, J., Saucedo-Cuevas, L. P., Oliván, M., Llobet‐Navàs, D., Putcha, P., Castro, V., Murga-Penas, E., Collazo-Lorduy, A., Castillo-Martín, M., et al. (2015) · Genes & Development · doi:10.1101/gad.262642.115 · Cited by 121
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
Yang, F., Hu, M., Lei, Q., Xia, Y., Zhu, Y., Song, X., Li, Y., Jie, H., Liu, C., Xiong, Y., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.63 · Cited by 119
Differential shedding of the two subunits of the interleukin‐6 receptor
Müllberg, J., Dittrich, E., Graeve, L., Gerhartz, C., Yasukawa, K., Taga, T., Kishimoto, T., Heinrich, P. C., & Rose‐John, S. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80507-q · Cited by 118
Serum interleukin-6 and -10 levels in patients with gastric cancer
Ikeguchi, M., Hatada, T., Yamamoto, M., Miyake, T., Matsunaga, T., Fukumoto, Y., Yamada, Y., Fukuda, K., Saito, H., & Tatebe, S. (2009) · Gastric Cancer · doi:10.1007/s10120-009-0509-8 · Cited by 116
STAT3 integrates cooperative Ras and TGF-β signals that induce Snail expression
Saitoh, M., Endo, K., Furuya, S., Minami, M., Fukasawa, A., Imamura, T., & Miyazawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.161 · Cited by 114
To, N. B., Nguyen, Y. T.-K., Moon, J. Y., Ediriweera, M. K., & Cho, S. K. (2020) · Nutrients · doi:10.3390/nu12061663 · Cited by 111
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Deisseroth, A., Ko, C., Nie, L., Zirkelbach, J. F., Zhao, L. Y., Bullock, J. M., Mehrotra, N., Valle, P. D., Saber, H., Sheth, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1678 · Cited by 110
Oh, K., Lee, O.-Y., Park, Y., Seo, M. W., & Lee, D. (2016) · BMC Cancer · doi:10.1186/s12885-016-2746-7 · Cited by 110
Wolfe, A. R., Trenton, N. J., Debeb, B. G., Larson, R. A., Ruffell, B., Chu, K., Hittelman, W. N., Diehl, M. R., Reuben, J., Ueno, N. T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12694 · Cited by 110
Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
Sanguinete, M. M. M., Oliveira, P. H. D., Martins-Filho, A., Micheli, D. C., Tavares‐Murta, B. M., Murta, E. F. C., & Nomelini, R. S. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1360342 · Cited by 110
Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels
Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H., Furuse, J., Inagaki, M., Higashi, S., Kato, H., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000335 · Cited by 109
STAT3 can be activated through paracrine signaling in breast epithelial cells
Lieblein, J., Ball, S., Hutzen, B. J., Sasser, A. K., Lin, H.-J. L., Huang, T. H. ‐., Hall, B. M., & Lin, J. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-302 · Cited by 109
Bozcuk, H. S., Uslu, G., Samur, M., Yıldız, M., Özben, T., Özdoğan, M., Artaç, M., Altunbaş, H., Akan, I., & Savaş, B. (2004) · Cytokine · doi:10.1016/j.cyto.2004.04.002 · Cited by 106
Riethmüller, S., Ehlers, J. C., Lokau, J., Düsterhöft, S., Knittler, K., Dombrowsky, G., Grötzinger, J., Rabe, B., Rose‐John, S., & Garbers, C. (2016) · Scientific Reports · doi:10.1038/srep25550 · Cited by 106
Khan, M. W., Saadalla, A., Ewida, A. H., Al-Katranji, K., Al-Saoudi, G., Giaccone, Z. T., Gounari, F., Zhang, M., Frank, D. A., & Khazaie, K. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2057-0 · Cited by 103
Oberg, H., Wesch, D., Grüssel, S., Rose‐John, S., & Kabelitz, D. (2006) · International Immunology · doi:10.1093/intimm/dxh396 · Cited by 103
Jin, K., Pandey, N. B., & Popel, A. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0981-3 · Cited by 99
IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function.
Böttcher, J. P., Schanz, O., Garbers, C., Zaremba, A., Hegenbarth, S., Kurts, C., Beyer, M., Schultze, J., Kastenmüller, W., Rose-John, S., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.008 · Cited by 98
Ruperto, N., the Pediatric Rheumatology Collaborative Study Group (PRCSG), Brunner, H. I., Żuber, Z. M., Tzaribachev, N., Kingsbury, D. J., Foeldvari, I., Horneff, G., Smolewska, E. B., Vehe, R. K., et al. (2017) · Pediatric Rheumatology · doi:10.1186/s12969-017-0212-y · Cited by 98
Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 96
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer
Tian, J., Chen, X. '., Fu, S., Zhang, R., Pan, L., Cao, Y., Wu, X., Xiao, H., Lin, H.-J. L., Lo, H., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05183-2 · Cited by 89
Self-citationXie, Q. M., Yang, Z., Huang, X., Zhang, Z., Li, J., Ju, J., Zhang, H., & Ma, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0744-3 · Cited by 88
Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition
Oh, E., Kim, Y. T., An, H., Sung, D., Cho, T.-M., Farrand, L., Jang, S., Seo, J. H., & Kim, J. Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31585 · Cited by 85
Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer
Bharti, R., Dey, G., Ojha, P. K., Rajput, S., Jaganathan, S. K., Sen, R., & Mandal, M. (2015) · Oncogene · doi:10.1038/onc.2015.466 · Cited by 81
Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer
Dobrzycka, B., Maćkowiak-Matejczyk, B., Terlikowska, K. M., Kulesza-Brończyk, B., Kinalski, M., & Terlikowski, S. J. (2013) · European Cytokine Network · doi:10.1684/ecn.2013.0340 · Cited by 80
Yan, I., Schwarz, J., Lücke, K., Schumacher, N., Schumacher, V., Schmidt, S., Rabe, B., Säftig, P., Donners, M. M. P. C., Rose‐John, S., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0515-207r · Cited by 80
Hu, Y., Yagüe, E., Zhao, J., Wang, L., Bai, J., Yang, Q., Pan, T., Zhao, H., Liu, J., & Zhang, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.036 · Cited by 78
Cai, G., Yu, W., Song, D., Zhang, W., Guo, J., Zhu, J., Ren, Y., & Kong, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.024 · Cited by 76
Duan, Z., Ames, R. Y., Ryan, M. B., Hornicek, F. J., Mankin, H. J., & Seiden, M. V. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0785-8 · Cited by 75
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Howie, L. J., Scher, N. S., Amiri‐Kordestani, L., Zhang, L., King‐Kallimanis, B. L., Choudhry, Y., Schroeder, J., Goldberg, K. B., Kluetz, P. G., Ibrahim, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3003 · Cited by 75
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models
Zeng, A., Yu, Y., Yao, Y.-Q., Yang, F.-F., Liao, M., Song, L.-J., Li, Y.-L., Yu, Y., Li, Y., Zeng, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23376 · Cited by 73
Löcken, H., Clamor, C., & Müller, K. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00247 · Cited by 71
Müller‐Newen, G., Köhne, C., Keul, R., Hemmann, U., Müller‐Esterl, W., Wijdenes, J., Brakenhoff, J. P. J., Hart, M. H. L., & Heinrich, P. C. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00837.x · Cited by 70
Lamertz, L., Rummel, F., Polz, R., Baran, P., Hansen, S., Waetzig, G. H., Moll, J. M., Floss, D. M., & Scheller, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar7388 · Cited by 70
Gyamfi, J., Lee, Y.-H., Min, B. S., & Choi, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47707-2 · Cited by 70
Danforth, D. N., & Sgagias, M. K. (1993) · PubMed · Cited by 69
Zhang, F., Wang, Z., Fan, Y., Xu, Q., Ji, W., Tian, R., & Niu, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024772 · Cited by 68
Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
Mehta, R. R., Katta, H., Alimirah, F., Patel, R., Murillo, G., Peng, X., Muzzio, M., & Mehta, R. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065113 · Cited by 68
Lee, H., Xue, J., Chou, P., Zhou, A., Yang, P., Conrad, C. A., Aldape, K., Priebe, W., Patterson, C., Sawaya, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3540 · Cited by 66
Jiang, X., Yang, D. C., Elliott, R. L., & Head, J. F. (2011) · PubMed · Cited by 61
Kim, S., Choi, H. S., Kim, J. H., Jeong, D. K., Kim, K.-S., & Lee, D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9296439 · Cited by 60
An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer
Sun, Z., Yao, Z., Liu, S., Tang, H., & Xiong, Y. (2006) · Immunobiology · doi:10.1016/j.imbio.2005.11.004 · Cited by 59
Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation
Haan, S., Keller, J. F., Behrmann, I., Heinrich, P. C., & Haan, C. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.010 · Cited by 59
Baron, J. M., Boster, B. L., & Barnett, C. M. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214527144 · Cited by 59
DeMichele, A. M., Gray, R. J., Horn, M., Chen, J., Aplenc, R., Vaughan, W. P., & Tallman, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2989 · Cited by 58
Interleukin-6 and pro inflammatory status in the breast tumor microenvironment
Sanguinetti, A., Santini, D., Bonafè, M., Taffurelli, M., & Avenia, N. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0529-2 · Cited by 57
Jiang, X. P., Yang, D. C., Elliott, R. L., & Head, J. F. (2000) · Cytokine · doi:10.1006/cyto.1999.0591 · Cited by 55
Loosen, S. H., Schulze-Hagen, M. F., Leyh, C., Benz, F., Vucur, M., Kuhl, C. K., Trautwein, C., Tacke, F., Bruners, P., Roderburg, C., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061766 · Cited by 54
Noori, S., Tavirani, M. R., Deravi, N., Rabbani, M. I. M., & Zarghi, A. (2020) · Iranian journal of pharmaceutical research · doi:10.22037/ijpr.2020.113103.14112 · Cited by 54
Yeh, K., Li, Y., Hsieh, L., Lu, C. H., Chou, W., Liaw, C., Tang, R., & Liao, S. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq010 · Cited by 53
Zhong, H., Davis, A., Ouzounova, M., Carrasco, R. A., Chen, C., Breen, S., Chang, Y. S., Huang, J., Liu, Z., Yao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0883 · Cited by 53
Sasser, K., Casneuf, T., Axel, A. E., King, P., Alvarez, J. D., Werbeck, J. L., Verhulst, T., Verstraeten, K., & Hall, B. M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s92414 · Cited by 51
Tsoi, H., Man, E. P. S., Chau, K. M., & Khoo, U. (2021) · Cancers · doi:10.3390/cancers13071511 · Cited by 51
Kotowicz, B. U., Fuksiewicz, M., Jońska‐Gmyrek, J., Bidziński, M., & Kowalska, M. M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3914-0 · Cited by 49
GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling
Khanna, P., Lee, J. S., Sereemaspun, A., Lee, H., & Baeg, G. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-27864-6 · Cited by 48
IL-6 variant is associated with metastasis in breast cancer patients
Abana, C. O., Bingham, B. S., Cho, J. H., Graves, A. J., Koyama, T., Pilarski, R., Chakravarthy, A. B., & Xia, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181725 · Cited by 47
Aryappalli, P., Shabbiri, K., Masad, R. J., Al-Marri, R. H., Haneefa, S. M., Mohamed, Y. A., Arafat, K., Attoub, S., Cabral-Marques, O., Ramadi, K. B., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184340 · Cited by 46
Growth inhibitory effect of Cucurbitacin E on breast cancer cells.
Lan, T., Wang, L., Xu, Q., Liu, W., Jin, H., Mao, W., Wang, X., & Wang, X. (2013) · Europe PMC (PubMed Central) · Cited by 45
O’Shaughnessy, J., DeMichele, A. M., Ma, C. X., Richards, P. D., Yardley, D. A., Wright, G. S., Kalinsky, K. M., Steis, R. G., Diab, S., Kennealey, G. T., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4770-6 · Cited by 45
Yang, Y., Zhou, H., Liu, W., Wu, J., Yue, X., Wang, J., Quan, L., Liu, H., Guo, L., Wang, Z., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9475 · Cited by 45
Li, Y., Gan, C., Zhang, Y., Yu, Y., Chen, F., Deng, Y., Zhang, Q., Yu, X. Y., Zhang, Y., Wang, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01195 · Cited by 45
Kishimoto, T., & Ishizaka, K. (1976) · PubMed · Cited by 44
Zhang, Z.-L., Jiang, Q.-C., & Wang, S. (2017) · Breast Cancer · doi:10.1007/s12282-017-0821-9 · Cited by 44
Raloxifene in breast cancer prevention
Gennari, L., Merlotti, D., Paola, V. D., & Nuti, R. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.3.259 · Cited by 40
CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling
Lin, C., Liao, W., Jian, Y., Peng, Y., Zhang, X., Ye, L., Cui, Y.-L., Wang, B., Wu, X., Xiong, Z., et al. (2017) · Oncogene · doi:10.1038/onc.2016.525 · Cited by 39
Microfluidic System to Analyze the Effects of Interleukin 6 on Lymphatic Breast Cancer Metastasis
Cho, H., Choi, J., Kim, K.-J., Shin, M., & Choi, J. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.611802 · Cited by 39
Oh, J. (1996) · Cytokine · doi:10.1006/cyto.1996.0055 · Cited by 35
Magidey, K., Cooper, T. J., Kveler, K., Normand, R., Zhang, T., Timaner, M., Raviv, Z., James, B. P., Gazit, R., Ronai, Z. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002856 · Cited by 35
Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista
Shi, W., Yan, D., Zhao, C., Xiao, M., Wang, Y., Ma, H., Liu, T., Qin, H., Zhang, C., Li, C., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.067 · Cited by 33
Ko, H., Lee, J., Kim, H., Kim, T., Han, Y. T., Suh, Y., Chun, J., Kim, Y., & Ahn, K. S. (2019) · Biomolecules · doi:10.3390/biom9050170 · Cited by 33
Yamashita, N., Kondo, M., Zhao, S., Li, W., Koike, K., Nemoto, K., & Kanno, Y. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.061 · Cited by 32
Won, H. S., Kim, Y. A., Lee, J. S., Jeon, E. K., An, H. J., Sun, D. S., Ko, Y. H., & Kim, J. S. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.826239 · Cited by 31
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
Ball, M. S., Bhandari, R., Torres, G. M., Martyanov, V., ElTanbouly, M. A., Archambault, K., Whitfield, M. L., Liby, K. T., & Pioli, P. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-63482-x · Cited by 31
Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line
Wakabayashi, H., Hamaguchi, T., Nagao, N., Kato, S., Iino, T., Nakamura, T., & Sudo, A. (2018) · Breast Cancer · doi:10.1007/s12282-018-0853-9 · Cited by 29
Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway
Qiu, C., Zhang, T., Zhu, X., Qiu, J., Jiang, K., Zhao, G., Wu, H., & Deng, G. (2018) · Reproductive Sciences · doi:10.1177/1933719118815582 · Cited by 28
Kearney, M., Franks, L. E., Lee, S. Y., Tiersten, A., Makower, D., Cigler, T., Mundi, P. S., Chi, D.-C., Goel, A., Klein, P., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06306-4 · Cited by 28
Labovsky, V., Martinez, L. M., Davies, K. M., Rivello, H. G., Calcagno, M. D. L., Matas, A., Vallone, V. B. F., Wernicke, A., Choi, H., & Chasseing, N. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.05.006 · Cited by 27
Shan, H., Yao, S., Yang, Y., & Yu, Q. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0254-4 · Cited by 26
A novel small-molecule inhibitor of IL-6 signalling
Zinzalla, G., Haque, M. R., Basu, B. P., Anderson, J., Kaye, S. L., Haider, S. M., Hasan, F., Antonow, D., Essex, S., Rahman, K. M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.117 · Cited by 25
Cited by
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
Wu, S., Wu, X., Wang, Q., Chen, Z., Li, L., Chen, H., & Qi, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156130 · Cited by 27
CD109, a master regulator of inflammatory responses
Batal, A., Garousi, S., Finnson, K. W., & Philip, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1505008 · Cited by 21
Metadata
- Authors
- Manore, S. G., Doheny, D. L., Wong, G. L., & Lo, H.-W.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-03-15
- Volume
- 12
- Pages
- 866014-866014
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W4220981167
- Cited by
- 307
- References
- 210
- FWCI
- 21.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.